Iovance Biotherapeutics (IOVA) Institutional Ownership
13F filers reported holding 63.8% of Iovance Biotherapeutics (IOVA) shares as of Jun 30, 2026, across 294 filers.
4 figures withheld by our checks. Each blank figure names its reason.
- Held by 13F filers
- 63.8%
- Jun 30, 2026
- 13F filers
- 294
- quarter ended Jun 30, 2026
- 13F value
- $1.2B
- 295.2M shares
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Berkowitz Noah | Chief Medical Officer | Acquired · Grant / award | 135,000Stock Options (Right to Buy) | — | ↗ |
| Sep 30, 2026 | Berkowitz Noah | Chief Medical Officer | Acquired · Grant / award | 180,000Restricted Stock Units | — | ↗ |
| Sep 30, 2026 | Berkowitz Noah | Chief Medical Officer | Acquired · Grant / award | 135,000Performance Stock Units | — | ↗ |
| Sep 8, 2026 | Vogt Frederick G | Interim CEO & General Counsel | Acquired · Option exercise | 15,626 | — | ↗ |
| Sep 8, 2026 | Vogt Frederick G | Interim CEO & General Counsel | Disposed · Tax withholding | 6,638 | $8.70 | ↗ |
| Sep 8, 2026 | Vogt Frederick G | Interim CEO & General Counsel | Disposed · Option exercise | 15,626Restricted Stock Units | — | ↗ |
| Sep 8, 2026 | BILINSKY IGOR | Chief Operating Officer | Acquired · Option exercise | 7,813 | — | ↗ |
| Sep 8, 2026 | BILINSKY IGOR | Chief Operating Officer | Disposed · Tax withholding | 3,976 | $8.70 | ↗ |
| Sep 8, 2026 | BILINSKY IGOR | Chief Operating Officer | Disposed · Option exercise | 7,813Restricted Stock Units | — | ↗ |
| Sep 8, 2026 | Puri Raj K. | Chief Regulatory Officer | Acquired · Option exercise | 9,766 | — | ↗ |
| Sep 8, 2026 | Puri Raj K. | Chief Regulatory Officer | Disposed · Tax withholding | 4,478 | $8.70 | ↗ |
| Sep 8, 2026 | Puri Raj K. | Chief Regulatory Officer | Disposed · Option exercise | 9,766Restricted Stock Units | — | ↗ |
| Sep 1, 2026 | Vogt Frederick G | Interim CEO & General Counsel | Acquired · Option exercise | 41,669 | — | ↗ |
| Sep 1, 2026 | Vogt Frederick G | Interim CEO & General Counsel | Disposed · Tax withholding | 17,702 | $8.28 | ↗ |
| Sep 1, 2026 | Vogt Frederick G | Interim CEO & General Counsel | Disposed · Option exercise | 41,669Restricted Stock Units | — | ↗ |
| Sep 1, 2026 | Puri Raj K. | Chief Regulatory Officer | Acquired · Option exercise | 5,470 | — | ↗ |
| Sep 1, 2026 | Puri Raj K. | Chief Regulatory Officer | Disposed · Tax withholding | 2,508 | $8.28 | ↗ |
| Sep 1, 2026 | Puri Raj K. | Chief Regulatory Officer | Disposed · Option exercise | 5,470Restricted Stock Units | — | ↗ |
| Sep 1, 2026 | BILINSKY IGOR | Chief Operating Officer | Acquired · Option exercise | 8,789 | — | ↗ |
| Sep 1, 2026 | BILINSKY IGOR | Chief Operating Officer | Disposed · Tax withholding | 4,472 | $8.28 | ↗ |
* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Iovance Biotherapeutics do institutions hold?
13F filers reported holding 63.8% of Iovance Biotherapeutics' shares as of Jun 30, 2026, across 294 filers.
How many 13F filers hold Iovance Biotherapeutics?
Iovance Biotherapeutics was held by 294 13F filers as of Jun 30, 2026.
Not investment advice.

